Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

September 30, 2008

Study Completion Date

December 31, 2008

Conditions
Parkinson's DiseaseCognitive ImpairmentDementia
Interventions
DRUG

Memantine

Active memantine and placebo, taken by mouth, will be titrated from 5mg a day to 20mg a day over 4 weeks. The subject will remain on 20mg (10mg twice a day) through week 24 unless unable to tolerate. The dose will be decreased as needed.

DRUG

Placebo Oral Tablet

Placebo, taken by mouth, will be titrated from 5mg a day to 20mg a day over 4 weeks. The subject will remain on 20mg (10mg twice a day) through week 24 unless unable to tolerate. The dose will be decreased as needed.

Trial Locations (1)

21287

Johns Hopkins Hospital, Baltimore

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Forest Laboratories

INDUSTRY

lead

Johns Hopkins University

OTHER